Maxence Duchemin Email

Ingénieur projet, recherche et développement . EverZom

Current Roles

Employees:
21
Revenue:
$2.1M
About
EverZom is a nanomedecine biotech companies developing a GMP compliant extracellular vesicle manufacturing platform based on a unique proprietary technology for pharmaceutical researchers developing breakthrough biotherapies. Extracellular vesicles which encompass exosomes, microvesicles and apoptotic bodies are the tools used by cells to communicate with each others. Extracellular vesicles have reparative and regenerative properties and are seen as an alternative to cell therapies for tissue regeneration. They eliminate many of the risks associated with cell therapies and carry significant benefits that the medical world considers to be game changing. There is a major challenge in the production of extracellular vesicles at commercial scale which is holding back the development of new therapies. EVerZom aims at overcoming this challenge with its breakthrough patented production method. This technology was developped in collaboration with the Laboratory Matières et Systèmes Complexes from the University of Paris and the CNRS. As an exosome CRO, we provide exosome characterization services, exosome quality control and analytics services, isolation, purification services, process development and manufacturing services.
EverZom Address
45, Rue des Saints-Pères
Paris, null
France
EverZom Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.